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ABSTRACT  
Rationale  Prognostication is important when counselling patients and defining 
treatment strategies in pulmonary arterial hypertension (PAH). Current biomarkers 
including MRI have been shown to predict mortality. However, their relative prognostic 
significance remains unclear.  
Objective  To determine the value of MRI metrics for prediction of mortality in PAH. 
Methods  Consecutive patients with PAH undergoing MRI were identified from the 
ASPIRE-Pulmonary-Hypertension-Registry. Multivariate Cox proportional hazards and 
receiver operating curve analysis (ROC) were used to determine the prognostic value of 
MRI in patients with PAH.  
Measurements and main results  During the follow-up period of 32±20 months 
576 patients were studied and 221 (38%) died. A derivation cohort (n=288, 115 deaths) 
and validation cohort (n=288, 106 deaths) were identified. On multivariate Cox 
regression analysis: RV-end-systolic-volume-index percent predicted by age and sex 
(RVESVI%pred) and pulmonary artery relative area change independently predicted 
mortality (p<0.01). A model of MRI and clinical data was accurate for predicting 
mortality at 1 and 3 years in the validation cohort, AUC 0.741 and AUC 0.815, 
respectively. The model was highly accurate in patients with IPAH, at 1 and 3 years in 
the validation cohort, AUC 0.803 and AUC 0.872.  
Conclusion  MRI measurements reflecting both RV structure and stiffness of the 
proximal pulmonary vasculature are independent predictors of outcome in PAH. In 
combination with clinical data MRI allows accurate prognostic evaluation in PAH, 
especially in IPAH. 
 
Abstract word count: 225 
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INTRODUCTION 
 
Over the last 2 decades there has been significant progress in the treatment of 
pulmonary arterial hypertension (PAH) but despite this it remains a progressive life 
shortening condition. Assessment of disease severity and estimating life expectancy is an 
important part of patient evaluation. It aids selection of treatment strategy, timing of 
transplantation and counselling of patients (1).  
 
Changes in the pulmonary vasculature in PAH cause an increase in right ventricular 
afterload, a reduction in cardiac output resulting in increasing breathlessness and a fall 
in exercise capacity (2). A number of measurements have been used to assess disease 
severity and estimate prognosis and include parameters reflecting symptomatic 
limitation (WHO function class (3)), impairment of right ventricular function (elevated 
right atrial pressure (3-5), reduced cardiac output (4-6) and reduced mixed venous 
oxygen saturation (5)) and measurements of exercise capacity (6 minute walk test 
distance (6MWT) (5, 6), and maximal oxygen uptake measured using cardiopulmonary 
exercise testing (7)).  In addition, multiparametric equations have been developed in 
attempts to improve the assessment of disease severity and aid prognostication (8, 9). 
All of these approaches are limited in part by inherent problems with reproducibility, 
subjective interpretation and the invasive nature of investigations such as cardiac 
catheterisation.  
 
Magnetic resonance imaging (MRI) provides accurate and reproducible information on 
cardiac morphology and function (10-12) and in addition also has sensitivity to changes 
in the pulmonary vasculature (13-16). Recently a number of studies have evaluated MRI 
as a tool to assess for the presence of PAH (14, 15, 17-21). Additionally studies have 
evaluated the prognostic value of MRI measurements; RV (right ventricular) end-
diastolic and end-systolic volumes, RV ejection fraction, and more recently RV-
pulmonary artery (PA) coupling metrics and PA relative area change (13, 16, 22-25) 
 3 
have all been shown to have predictive value in patients with PAH. However, these 
studies have often been performed in relatively small numbers of patients and have 
concentrated on a limited number of parameters. The aim of this study was to 
investigate the prognostic value of cardiopulmonary MRI metrics in a large PAH registry. 
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METHODS 
 
Patients 
Consecutive patients diagnosed with PAH, at a pulmonary hypertension referral centre, 
who underwent MRI, were identified from January 2008 to February 2015. Patients 
referred with suspected pulmonary hypertension underwent systematic evaluation as 
previously described in the ASPIRE registry (26), including lung function, exercise 
testing, high resolution computed tomography (CT) and CT pulmonary angiography, MRI 
and right heart catheterisation. Data was also retrieved for treatment at the time of 
census or death and was recorded as oral monotherapy (phosphodiesterase 5 inhibitor or 
endothelin receptor antagonist), oral combination therapy (phosphodiesterase 5 inhibitor 
and endothelin receptor antagonist), prostanoid therapy or calcium channel blocker 
therapy. Ethical approval for this analysis of imaging techniques and routinely collected 
data was granted by our institutional review board, ref c06/Q2308/8. 
 
MR image acquisition  
MR imaging was performed using an 8 channel cardiac coil on a GE HDx (GE Healthcare, 
Milwaukee, USA) whole body scanner at 1.5T. Short axis cine images were acquired 
using a cardiac gated multi-slice balanced SSFP sequence (20 frames per cardiac cycle, 
slice thickness 8mm, FOV 48, matrix 256 x 256, BW 125 KHz/pixel, TR/TE 3.7/1.6 ms). 
A stack of images in the short axis plane with slice thickness of 8 mm (2mm inter-slice 
gap) were acquired fully covering both ventricles from base to apex. End-systole was 
considered to be the smallest cavity area. End-diastole was defined as the first cine 
phase of the R-wave triggered acquisition or largest volume. Through plane phase 
contrast imaging was performed orthogonal to the main pulmonary trunk. Phase contrast 
imaging parameters were as follows: repetition time, TR 5.6 ms; echo time, TE 2.7 ms; 
slice thickness, 10 mm; field of view, 48 cm, bandwidth, 62.5 kHz; matrix, 256 x 128; 
20 reconstructed cardiac phases; and velocity encoding of flow, 150 cm/s. Patients were 
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in the supine position with a surface coil and with retrospective ECG gating. 
 
Image analysis 
Image analysis was performed on a GE Advantage Workstation 4.1 with the observer 
blinded to the patient clinical information, and cardiac catheter parameters. Right and 
left endocardial and epicardial surfaces were manually traced from the stack of short-
axis cine images, using proprietary MR workstation software to obtain RV end-diastolic 
(RVEDV) and end-systolic (RVESV), and LV end-diastolic (LVEDV) and end-systolic 
volumes (LVESV). From end-diastolic and end-systolic volumes, RV and LV ejection 
fraction (RVEF and LVEF) and RV and LV stroke volume were calculated. With the 
exception of RVEF and LVEF, these measurements were indexed for BSA. Based on 
previous work, stroke volume (SV) was considered to be the most accurate from LV 
volumetry (27) and was used for MRI estimation of RV-PA coupling. For calculation of 
ventricular mass the interventricular septum was considered as part of the LV. Right 
ventricular end-diastolic mass (RV mass) and left ventricular end-diastolic mass were 
derived (LV mass). Ventricular mass index (VMI) was defined as RV mass divided by LV 
mass, as previously described (18). Maximal and minimal PA areas were measured, and 
relative area change was defined by the following equation: RAC= (maximum area-
minimum area)/minimum area (14, 28). See Figure 1. Inter-observer reproducibility 
was tested in 30 randomly selected cases. 
 
Right heart catheterisation and clinical assessment 
Right heart catheterisation was performed using a balloon-tipped 7.5 Fr thermodilution 
catheter (Becton-Dickinson, USA). Right heart catheterisation was usually performed via 
the internal jugular vein using a Swan-Ganz catheter.  Features at right heart 
catheterisation required to define PAH were mean pulmonary artery pressure (mPAP) 
25 mmHg at rest with a pulmonary arterial wedge pressure (PA:3RIPP+J(29). 
Pulmonary vascular resistance (PVR) was determined as follows: PVR = (mPAP - 
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PAWP)/Cardiac output (CO). CO was measured by thermodilution technique. Diagnostic 
classification of the form of PAH was made using standard criteria following 
multiprofessional assessment (26). To be included in the study patients were also 
required to have received treatment with PAH therapy during the study period. 
Coupling measurements  
As previously described, right ventricular elastance (Ees) was estimated as mPAP divided 
by RVESV index (30). Pulmonary arterial elastance (Ea) was estimated using mPAP-
PCWP divided by SV index. Therefore, Ees/Ea by a combined right heart catheterisation 
and MRI approach was defined as follows (mPAP/RVESV index)/(mPAP-PCWP)/SV index). 
MRI estimated Ees/Ea  was defined by SV/RVESV (24, 30-32). Table 1 summarises the 
coupling measurements and pulmonary arterial relative area change metrics. 
Statistics 
The interval from evaluation with MRI until all cause death or census was regarded as 
the follow-up period. Individual analyses of mortality, at 1 and 3 years were also 
performed. A census was performed on the 15th of July 2016. Log-log plots were 
produced for each variable to assess proportional hazards; continuous variables were 
dichotomised for this analysis. CMR volumetric measurements indexed for BSA were 
corrected for age and gender and presented as percentage (%) predicted as per prior 
data by Maceira et al (33) and Kawut et al (34). The prognostic value of MRI derived 
biventricular volume, mass and function, PA measurements, mPAP, mean right atrial 
pressure (mRAP), CI, PVR, mixed venous oxygen saturation (SvO2), RV-PA coupling 
indices and patient age, sex and WHO functional class were assessed using univariate 
Cox proportional hazards regression analysis. Variable scaling was performed to allow 
direct comparison of hazard ratios of all continuous variables by dividing individual 
values by the standard deviation of the variable. In addition, Bonferroni correction was 
performed on univariate predictors. Highly correlated variables (r>0.8) that were 
significant at univariate Cox analysis were entered separately into the model. 
Multivariate analysis with a forward stepwise approach was performed for demographic, 
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CMR and right heart catheterisation data significant at univariate analysis (p<0.2). IPAH, 
the largest diagnostic population, was used as the reference category for multivariate 
analysis and combination therapy, being the largest therapy group was used as the 
reference category for multivariate analysis.   Derivation and validation cohorts were 
constructed to develop models encompassing MRI data alone and MRI and clinical data 
combined. In the derivation cohort variables significant at p<0.2 were entered into a Cox 
proportional hazards regression model. The model was tested in the validation cohort. 
Kaplan-Meier analysis was used to assess the prognostic value of MRI volumetric 
measurements using median threshold values. Groups were compared using the log-
rank (Mantel-Cox) test. Receiver operating characteristic (ROC) analysis and the Mann-
Whitney U test were employed to assess prognostic significance of candidate predictors 
of mortality with area under the curve data presented for mortality at 1 and 3 years. The 
derivation cohort was utilized to develop predictive thresholds for CMR parameters. 
Statistical analysis was performed using SPSS 19 (SPSS, Chicago, Ill) and for 
presentation of the data GraphPad Prism 6.04 (GraphPad Software, San Diego, Calif) 
software was used. A p-value < 0.05 was considered statistically significant. 
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RESULTS 
 
Five hundred and seventy six patients with PAH were identified. Three hundred and 
ninety eight patients were incident and treatment naïve, and one hundred and seventy 
eight patients were prevalent PAH patients on PAH therapy, see Figure 2. Table 2 
shows the demographic, MRI and right heart catheterisation data for i) the total study 
cohort, ii) incident patients with PAH who were treatment naïve and iii) prevalent 
patients with PAH on PAH treatment. The study group included 260 patients with 
idiopathic pulmonary arterial hypertension (IPAH), 195 patients with PAH associated with 
connective tissue disease, 63 patients with congenital heart disease, 58 patients with 
PAH associated with HIV, portal hypertension or drugs and toxins. Table 3 summarises 
the baseline characteristics of incident treatment naïve patients with IPAH and PAH-CTD. 
 
Survival analyses 
 
Full cohort 
During the follow-up period 221 patients (38%) died (mean follow up was 32 (SD 20) 
months). Table 4 presents the univariate cox proportional hazards regression analysis 
data for demographic, hemodynamic and MRI data. MRI measures of RV size and 
function: RVEDV %pred (p=0.003), RVESV %pred (p<0.0001), RVEF %pred (p<0.0001) 
and invasive and non-invasive MRI derived Ees/Ea (p<0.001) predicted mortality at 
univariate Cox regression analysis. Both pulmonary artery relative area change (RAC) 
and pulmonary arterial distensibility (p<0.0001) predicted mortality at univariate Cox 
regression analysis following Bonferroni correction. Age>50, WHO functional class IV and 
SvO2 (all p<0.0001) were also predictive of mortality, all remaining significant following 
Bonferroni correction. At multivariate analysis increased RVESVI %pred (p=0.005) 
reduced PA relative area change (p=0.008), age >50 (p<0.0001), the presence of CTD 
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(p=0.039), and decreased SvO2 (p=0.006) and oral monotheray as compared to 
combination oral therapy (p=0.006) were associated with worse outcome. Figure 3 
shows Kaplan Meier plots for RVESVI %pred and PA relative area change above and 
below median thresholds.  
 
Incident and prevalent cases 
Incident treatment naïve patients were older (p<0.0001) and had worse outcome at Cox 
regression analysis (hazard ratio 2.338 (1.603 to 3.408) (p<0.0001) than prevalent 
patients with PAH on therapy. Incident patients had more severe haemodynamic 
impairment with lower SvO2 (p=0.003) and CI (p<0.0001) and on MRI had evidence of 
more severe disease with higher RVESVI (%pred) (p<0.0001) and lower RVEF (%pred), 
LVEDV (%pred) (p<0.0001) and PA relative area change (p<0.0001), Table 2. At 
multivariate Cox regression analysis of incident patients the same predictors were 
significant as in the full cohort inclusive of incident and prevalent cases; age >50, lower 
SvO2 and lower PA relative area change were independent indicators of adverse 
outcome, lower RVESVI %pred and combination oral therapy predicted improved 
survival, Table 5. 
 
Subgroup analysis ±IPAH and PAH-CTD 
In incident treatment naïve patients with IPAH there were a number of independent 
variables that predicted outcome at multivariate analysis: RVESVI %pred (p=0.001), Ees 
(p=0.035), low SvO2 (p=0.002), age>50 (p=0.010) and male sex (p=0.029), Table 5. 
At ROC analysis, RVESVI %pred was predictive of mortality in patients with IPAH at 1 
and 3 years, AUC=0.716 and 0.735 respectively.  
 
In incident treatment naïve patients with PAH-CTD, PA stiffness measured by PA relative 
area change (p=0.003) and Ees/Ea (combined invasive/non-invasive metric) (p=0.010) 
and treatment (oral monotherapy as compared to combination therapy, p=0.019) were 
independent predictors of outcome at multivariate analaysis, Table 5. In PAH-CTD PA 
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relative area change was predictive of mortality at 1 and 3 years, AUC 0.640 and AUC 
0.696, respectively. 
 
Prognostic model and validation  
A derivation cohort (n=288, 115 deaths) and validation cohort (n=288, 106 deaths) 
were identified. There was no significant difference in age, sex, WHO functional class, 
MRI data, right heart catheter hemodynamics, time to death or census, or the proportion 
of CTD, IPAH or congenital heart disease or male patients between the validation and 
derivation cohorts (all p>0.05). In the derivation cohort the following model was derived 
from multivariate Cox regression analysis of MRI and clinical data: Prognostic score = 
(RVESVI (%pred) x 0.208) ± (PA relative area change x 0.208) + (WHO FC X 0.458) + 
(Age x 0.031) ± (male = 0.488 or female = 0.976) + (0.304 if CTD). In the validation 
cohort the model showed the following accuracy, AUC 0.741 and AUC=0.815 at 1 and 3 
years. A model based on MRI parameters alone (RVESVI (%pred) x 0.325 - PA relative 
area change x 0.295) demonstrated the following prognostic accuracy at 3 years in all 
PAH (AUC=0.741), in IPAH AUC=0.820 (Figure 4) and in PAH-CTD, AUC=0.690. 
 
Optimal thresholds at ROC analysis, were identified in the derivation cohort for RVESVI 
(%pred): 180%, the MRI model: 0.13 units and the model including MRI and clinical 
data: 3.0 units. Table 6 presents the sensitivity, specificity, positive and negative 
predictive value data for these optimal thresholds for 3 year mortality. There was no 
significant difference at ROC analysis for predicting mortality, between current methods 
of correcting MRI data for age, sex and body size (Maceira et al (33) and Kawut et al 
(34)), RVEDV (p=0.955), RVEF (p=0.236) and RVEDM (p=0.635). 
 
Reproducibility of MR indices 
Excellent inter-observer reproducibility was identified for RV end-diastolic and end-
systolic volume measurements; with high intra- class correlation coefficients 
demonstrated ICC 0.959 and 0.991 respectively. The agreement was found to be 
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marginally weaker for RV ejection fraction and stroke volume measurements 0.957 and 
0.928 respectively.  MRI estimated Ees/Ea was highly reproducible, ICC 0.977 (CI 0.953 
to 0.989). PA relative area change was reproducible, ICC 0.891 (0.655 to 0.957).  Intra-
observer agreement was also high for LV volume measurements (ICC 0.973 to 0.986) 
and similarly high intra-observer agreement for RV volume measurements was shown 
(ICC 0.940 to 0.996).  
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DISCUSSION  
 
This study confirms the independent prognostic value, of MRI measurements reflecting 
RV volume and stiffness of the proximal pulmonary vasculature, in a large cohort of 
patients with PAH. In addition, a model including MRI measurements of RV end-systolic 
volume (%pred) and PA relative area change in combination with clinical data, age, sex, 
WHO FC and the presence or absence of an underlying connective tissue disease, 
improves prognostication in pulmonary arterial hypertension.  
 
Many indices of RV size and function have been proposed as prognostic markers in the 
assessment of patients with pulmonary hypertension, however, previous studies have 
often been performed in relatively small and selected cohorts of patients. Given the large 
number of patients in the current study and number of deaths during the follow-up 
period it has provided an opportunity to assess the clinical utility and relative value of a 
number of candidate MRI prognostic markers in clinical practice. This study confirms the 
prognostic value of RV volumes and ejection fraction measured at MRI shown in previous 
studies (23, 25). Although in clinical practice physicians have traditionally favoured 
single measurements such as RV ejection fraction, this study demonstrates the added 
prognostic value of combining a measure of the RV (RVESVI %pred) and a measure of 
changes in the pulmonary vasculature (pulmonary artery relative area change). 
 
A criticism of relatively simple measures thought to reflect right ventricular function such 
as volumes and ejection fraction is that these metrics are not load independent (35). 
Recently more complex measurements reflecting RV-PA coupling, described by the 
simultaneous relationship between two load independent metrics, RV contractility (Ees) 
and afterload (Ea) (35) have been proposed as superior to volumetric measurements. 
Previous work has shown that parameters such as Ees and Ea can be estimated from 
standard data collected from right heart catheterisation and MRI (30), rather than using 
conductance catheters not typically used in routine clinical practice. In addition a 
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completely non-invasive MR based approach and techniques using gated blood pool 
scintingraphy, can yield measures of RV-PA coupling acknowledging previously described 
limitations (24, 30-32, 36).  A recent study has shown the superior prognostic 
significance of an MRI derived estimate of right ventricular-arterial coupling Ees/Ea over 
other invasive and non-invasive measures of RV function (24). In the present study, 
although MRI estimated Ees/Ea and combined MRI and RHC Ees/Ea, were prognostic at 
univariate analysis they were not found to be independently prognostic in the full cohort. 
However, in the subgroup analysis in patients with PAH-CTD in contrast to IPAH 
combined MRI and RHC Ees/Ea was independently predictive of mortality. 
 
Independent prognostic markers differed between IPAH and PAH-CTD. In IPAH measures 
of RV size and function, RV end systolic volume and Ees were independently prognostic, 
in addition to age, sex and SvO2. Whereas, independent prognostic markers in PAH-CTD 
were pulmonary arterial relative area change and Ees/Ea (combined invasive/MRI). 
These differences are likely to reflect the individual pathophysiology and therapy 
responsiveness of PAH subgroups and reinforces that subgroups have differing 
prognostic markers.  
 
Pulmonary artery relative area change was found to be an independent prognostic 
marker in the full cohort, and our data suggests that the stiffness of the pulmonary 
vasculature has independent prognostic value in addition to baseline measurements 
reflecting RV function. The present study shows comparable univariate prognostic value 
of non-invasive PA relative area change and PA distensibility, and no significant 
difference at ROC analysis between the two measures. This may reflect the close 
correlation between these two metrics (r=0.88).  
 
Patient age has been shown to strongly predict mortality in several PAH cohorts (37, 
38).  These studies have also demonstrated that the range and average age of patients 
has risen significantly over the last decade making adjustments for age and sex more 
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relevant in the current era for accurate individual risk stratification (39). RV end-systolic 
volume corrected for age, sex and body surface was a significantly stronger predictor of 
mortality than when adjusted for body surface area alone, highlighting the need to 
adjust volumetric measurements for individual patients. We have corrected our data 
using data by Maceira et al (33) due to similarity in RV analysis technique for the main 
analyses, however, other normative RV data, such as Kawut et al (34), is available and 
demonstrated similar prognostic value in our cohort of patients. In the present study 
RVESVI%pred rather than RVEDV%pred was independently prognostic; increased RVESV 
implies enlargement of the RV in addition to a loss of systolic function and may explain 
the greater prognostic importance. This finding mirrors data in chronic heart failure, in 
which increasing RVESV has been shown to be an independent predictor of mortality 
(40). 
 
Interestingly, in the present study patients on combination therapy with a 
phosphodiesterase inhibitor and endothelin receptor antagonist had a better outcome 
than patients on phosphodiesterase inhibitor or endothelin receptor antagonist alone. 
This is consistent with a prospective double-blinded study, which showed the benefit of 
combination therapy over monotherapy in patients with PAH (41) in reducing clinical 
worsening and a MRI focused study of combination therapy in systemic sclerosis which 
demonstrated improvements in RV function(42).  
 
In clinical practice assessments are based on integrating available information and there 
has been a move towards developing scoring systems to aid prognostication. ROC curves 
are frequently used to assess the value of diagnostic tests, however, there is only limited 
data on assessing the prognostic value of candidate prognostic markers in PAH using 
ROC analysis. The prognostic value of a single MRI measurement was improved by 
combining MRI metrics and further improved by incorporating additional clinical data, 
obtaining ROC values equal to or better than previous studies in cardiac disease (43) and 
PAH (44).  
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Limitations 
This is a single centre study. There are limitations to estimating RV-PA coupling non-
invasively as previously described. Race has been shown to have an independent effect 
on RV volumes; however, the demographic of our population does not allow direct 
comparison with the published reference data (34) and we have not adjusted MRI data 
for race in this study. 
 
Conclusions 
MRI measurements of RV structure and function are highly reproducible and have 
prognostic value.  Combining MRI measures of RV function and pulmonary artery 
stiffness with clinical data further improves prognostication in patients with pulmonary 
arterial hypertension. 
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Table 1 Description of and coupling measurements and PA stiffness metric and 
pulmonary arterial relative area change 
 
Key metrics Measurement description Equation 
Ea (mmHg/ml/m2) Arterial elastance (mPAP-PAWP)/stroke volume index 
 
Ees (mmHg/ml/m2) Right Ventricular 
elastance 
 
mPAP/RV end systolic volume index 
Ees/Ea (ratio) PA-RV coupling metric (mPAP/RV end systolic 
volume)/[(mPAP-PAWP)/stroke 
volume] 
 
MRI Ees/Ea (ratio) Non-invasive PA-RV 
coupling metric 
 
Stroke volume/RV end systolic volume 
PA relative area change 
(%) 
Non-invasive 
measurement of PA 
stiffness 
(Maximal pulmonary arterial area-
minimal pulmonary arterial 
area)/minimal pulmonary arterial area 
 
Distensibility (%/PP) Measurement of PA 
stiffness 
PA relative area change/pulse pressure 
mPAP=mean pulmonary artery pressure, PAWP=pulmonary arterial wedge pressure, RV=right 
ventricle, PA=pulmonary artery, MRI=magnetic resonance imaging, PP=pulse pressure 
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Table 2 Baseline demographic, MRI and right heart catheterisation (RHC) data. 
N=576 All patients 
 
Incident patients  
N=398 
Prevalent patients 
N=178 
P value 
Demographics     
  Age (yrs) 57 (16) 60 (15) 52 (17) <0.0001 
  Gender (female %) 
M/F 
182/394 132/266 50/128 0.264 
  WHO functional class  
    I 
    II 
    III 
    IV 
 
5 
50 
451 
70 
 
2 
32 
308 
56 
 
3 
17 
141 
14 
 
Subgroup     
  IPAH 260 179 80 0.946 
  CTD 195 147 48 0.022 
  Congenital 63 31 32 <0.0001 
  Other (portal, HIV and 
drugs) 
58 41 18 0.883 
PAH therapy     
   Monotherapy oral 155 126 29 <0.0001 
   Combination oral  308 205 104 0.138 
   Prostanoid 107 62 45 0.005 
RHC    
  mPAP (mmHg) 48 (13) 48 (13) 45 (14) 0.090 
  mRAP (mmHg) 10 (6) 10 (3) 10 (5) 0.369 
  PAWP (mmHg) 10 (3) 10 (3) 11 (3) 0.046 
  Svo2 (%) 64 (10) 63 (9) 67 (10) 0.003 
  CI (L.min-1.m-2) 2.8 (0.9) 2.7 (0.8) 3.3 (1.1) <0.0001 
  PVRI (Wood units*m2) 16 (8.1) 15.7 (7.9) 14.0 (9.5) 0.206 
Cardiac MR indices     
  RVEDVI (ml/m2) 
  RVEDVI %pred 
94 (35) 
128 (47) 
94 (33) 
129 (45) 
94 (40) 
124 (52) 
0.978 
0.233 
  RVESVI (ml/m2) 
  RVESVI %pred 
59 (29) 
246 (125) 
62 (28) 
262 (126) 
54 (30) 
210 (117) 
0.005 
<0.0001 
  RVEF (%) 
  RVEF %pred 
39 (14) 
58 (22) 
36 (14) 
54 (21) 
44 (13) 
67 (20) 
<0.0001 
<0.0001 
  RVSVI (ml/m2) 
  RVSVI %pred 
35 (16) 
71 (33) 
33 (14) 
67 (30) 
40 (19) 
20 (19) 
<0.0001 
<0.0001 
  LVEDVI (ml/m2) 
  LVEDVI %pred 
54 (19) 
69 (24) 
50 (16) 
66 (21) 
61 (23) 
79 (30) 
<0.0001 
<0.0001 
  LVESVI (ml/m2) 
  LVESVI %pred 
18 (9) 
73 (38) 
17 (8) 
70 (35) 
20 (11) 
79 (46) 
0.001 
0.049 
  LVEF (%) 
  LVEF %pred 
67 (11) 
98 (15) 
66 (11) 
97 (16) 
68 (9) 
101 (14) 
0.036 
0.008 
  LVSVI (ml/m2) 
  LVSVI %pred 
26 (14) 
52 (28) 
23 (12) 
47 (24) 
12 (16) 
65 (32) 
<00001 
<0.0001 
  RVEDMI 35 (20) 36 (20) 34 (21) 0.330 
  RVEDMI %pred 124 (70) 127 (70) 114 (70) 0.120 
  PA forward flow index  
(l/min/m2) # 
3.2 (1.4) 3.0 (1.3) 3.6 (1.5) <0.0001 
PA stiffness metrics     
  PA relative area 
change# 
12 (8) 11 (7) 14 (9) <0.0001 
  PA distensibility* 0.28 (0.31) 0.25 (0.30) 0.37 (0.31) 0.003 
RV PA coupling 
metrics 
    
  Ea (mmHg/ml/m2)* 2.0 (1.4) 2.2 (1.4) 1.4 (1.2) <0.0001 
  Ees (mmHg/ml/m2)* 0.95 (0.246) 0.9 (0.5) 1.0 (0.5) 0.024 
  Ees /Ea (ratio)* 0.80 (0.83) 0.7 (0.7) 1.3 (1.2) <0.0001 
  MRI Ees /Ea (ratio) 0.74 (0.47) 0.7 (0.4) 0.9 (0.5) <0.0001 
*N=379 #N=555. Values presented as mean (standard deviation) unless otherwise stated. WHO= world health 
organisation, IPAH = idiopathic pulmonary arterial hypertension, CTD = connective tissue disease,  
mRAP=mean right atrial pressure, mPAP=mean pulmonary artery pressure, PCWP=pulmonary capillary wedge 
pressure, PVR=pulmonary vascular resistance, CI=cardiac index, Svo2= mixed venous oxygen saturations, 
RVEDVI=right ventricular end-diastolic volume index, RVESVI=right ventricular end-systolic volume index, 
RVEF=right ventricular ejection fraction, LVEDVI=left ventricular end-diastolic volume index, LVESVI=left 
ventricular end-systolic volume index, LVEF=left ventricular ejection fraction, LVSVI=left ventricular stroke 
volume index, VMI=ventricular mass index, Ea = arterial load and Emax = RV elastance. 
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Table 3 Demographics and comparison of incident treatment naïve patients IPAH and 
PAH-CTD. 
 IPAH n=179 
 
PAH-CTD n=147 P value 
Demographics    
  Age (yrs) 60 (16) 63 (13) 0.093 
  Gender  M/F 73/106 31/116 <0.0001 
  WHO functional class  
    I 
    II 
    III 
    IV 
 
0 
14 
128 
137 
 
1 
9 
121 
16 
 
 
PAH therapy    
   Monotherapy oral 61 49 0.888 
   Combination oral  82 82 0.074 
   Prostanoid 36 16 0.024 
RHC   
  mPAP (mmHg) 52 (11) 43 (12) <0.0001 
  mRAP (mmHg) 11 (5) 10 (6) 0.061 
  PAWP (mmHg) 10 (3) 10 (3) 0.207 
  Svo2 (%) 61 (9) 65 (8) <0.0001 
  CI (L.min-1.m-2) 2.5 (0.8) 2.9 (0.8) <0.0001 
  PVRI (Wood units*m2) 18.1 (7.5) 13.1 (8.2) <0.0001 
Cardiac MR indices    
  RVEDVI %pred 134 (43) 117 (37) <0.0001 
  RVESVI %pred 286 (126) 235 (116) <0.0001 
  RVEF %pred 48 (18) 57 (22) <0.0001 
  RVSVI %pred 63 (19) 64 (23) 0.758 
  LVEDVI %pred 63 (19) 67 (18) 0.095 
  LVESVI %pred 72 (38) 67 (18) 0.136 
  LVEF %pred 93 (16) 101 (15) <0.0001 
  LVSVI %pred 41 (21) 51 (25) <0.0001 
  RVEDMI %pred 215 (119) 166 (93) <0.0001 
  PA forward flow index  
(l/min/m2)  
2.6 (1.0) 3.0 (0.9) <0.0001 
PA stiffness metrics    
  PA relative area 
change 
10 (6) 11 (8) 0.089 
  PA distensibility 0.18 (0.15) 0.31 (0.35) 0.001 
RV PA coupling 
metrics 
   
  Ea (mmHg/ml/m2 1.8 (1.9) 1.3 (1.3) 0.003 
  Ees (mmHg/ml/m2) 0.89 (0.34) 0.98 (0.43) 0.047 
  Ees /Ea (ratio) 0.45 (0.34) 0.95 (0.84) <0.0001 
  MRI Ees /Ea (ratio) 0.54 (0.31) 0.75 (0.47) <0.0001 
Values presented as mean (standard deviation) unless otherwise stated. WHO= world health organisation, 
IPAH = idiopathic pulmonary arterial hypertension, CTD = connective tissue disease,  mRAP=mean right atrial 
pressure, mPAP=mean pulmonary artery pressure, PCWP=pulmonary capillary wedge pressure, 
PVR=pulmonary vascular resistance, CI=cardiac index, Svo2= mixed venous oxygen saturations, 
RVEDVI=right ventricular end-diastolic volume index, RVESVI=right ventricular end-systolic volume index, 
RVEF=right ventricular ejection fraction, LVEDVI=left ventricular end-diastolic volume index, LVESVI=left 
ventricular end-systolic volume index, LVEF=left ventricular ejection fraction, LVSVI=left ventricular stroke 
volume index, VMI=ventricular mass index, Ea = arterial load and Emax = RV elastance. 
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Table 4 Univariate Cox proportional hazards regression analysis showing prognostic 
significance of demographic, right heart catheterisation (RHC) and MRI data for the full 
cohort 
 
N=576, 221 deaths 
 
Univariate 
Hazard ratio 
 
 
Scaled univariate 
Hazard ratio 
 
 
 
P value 
 
Demographics 
   
  Age (dichotomised   
DQG 
4.092 (2.697 to 6.208)  <0.0001+ 
  Gender (female %) 0.794 (0.600 to 1.049)  0.105 
  WHO FC     
    I&II vs III&IV 1.876 (1.126 to 3.125)  0.016 
    I-III vs IV 2.636 (1.912 to 3.634)  <0.0001+ 
  IPAH 0.873 (0.669 to 1.140)  0.319 
  CTD 1.572 (1.202 to 2.056)  0.001 
  Congenital 0.389 (0.212 to 0.713)  0.002 
  Other 0.971 (0.625 to 1.509)  0.897 
PAH therapy    
   Monotherapy oral 1.658 (1.281 to 2.239)  <0.0001 
   Combination oral  0.684 (0.524 to 0.892)  0.005 
   Prostanoid 0.946 (0.679 to 1.317)  0.742 
RHC    
  mPAP (mmHg) 0.997 (0.987 to 1.008) 0.968 (0.842 to 1.112) 0.643 
  mRAP (mmHg) 1.019 (0.994 to 1.045) 1.112 (0.967 to 1.279) 0.137 
  PAWP (mmHg) 0.978 (0.938 to 1.019) 0.926 (0.804 to 1.067) 0.291 
  Svo2 (%) 0.969 (0.955 to 0.983) 0.738 (0.644 to 0.847) <0.0001+ 
  CI (L.min-1.m-2) 0.826 (0.698 to 0.979) 0.840 (0.720 to 0.981) 0.027 
  PVRI (dyn.s.cm-3) 1.008 (0.991 to 1.025) 1.065 (0.931 to 1.218) 0.359 
Cardiac MR indices    
  RVEDVI %pred 1.005 (1.002 to 1.007) 1.244 (1.107 to 1.399) <0.0001+ 
  RVESVI %pred 1.003 (1.002 to 1.004) 1.403 (1.256 to 1.567) <0.0001+ 
  RVEF %pred 0.987 (0.981 to 0.993) 0.754 (0.662 to 0.860) <0.0001+ 
  RVSVI %pred 0.999 (0.995 to 1.003) 0.956 (0.838 to 1.091) 0.506 
  LVEDVI %pred 0.990 (0.984 to 0.996) 0.998 (0.996 to 0.999)       0.002 
  LVESVI %pred 0.998 (0.994 to 1.002) 0.999 (0.998 to 1.001) 0.359 
  LVEF %pred 0.993 (0.985 to 1.001) 0.898 (0.790 to 1.022) 0.103 
  LVSVI %pred 0.990 (0.983 to 0.996) 0.744 (0.619 to 0.896) 0.002 
  RV EDM %pred 1.001 (1.000 to 1.002) 1.149 (1.009 to 1.308) 0.036 
  PA forward flow index  
(l/min/m2) # 
0.851 (0.761 to 0.951) 0.797 (0.682 to 0.932) 0.004 
PA stiffness metrics    
  PA relative area 
change# 
0.951 (0.932 to 0.971) 0.672 (0.569 to 0.794) <0.0001+ 
  PA distensibility* 0.134 (0.045 to 0.401) 0.536 (0.381 to 0.754) <0.0001+ 
RV PA coupling 
metrics 
   
  Ea (mmHg/ml/m2)* 1.036 (0.942 to 1.140) 1.051 (0.920 to 1.201) 0.462 
  Ees (mmHg/ml/m2)* 0.921 (0.831 to 1.020) 0.793 (0.667 to 0.944) 0.112 
  Ees /Ea (ratio)* 0.549 (0.401 to 0.753) 0.777 (0.673 to 0.896) 0.001+ 
  MRI Ees /Ea (ratio) 0.525 (0.375 to 0.736) 0.739 (0.621 to 0.866) <0.0001+ 
*N=379 #N=555. +Significant after Bonferonni correction. WHO= world health organisation, IPAH = idiopathic 
pulmonary arterial hypertension, CTD = connective tissue disease,  mRAP=mean right atrial pressure, 
mPAP=mean pulmonary artery pressure, PCWP=pulmonary capillary wedge pressure, PVR=pulmonary vascular 
resistance, CI=cardiac index, Svo2= mixed venous oxygen saturations, RVEDVI=right ventricular end-diastolic 
volume index, RVESVI=right ventricular end-systolic volume index, RVEF=right ventricular ejection fraction, 
LVEDVI=left ventricular end-diastolic volume index, LVESVI=left ventricular end-systolic volume index, 
LVEF=left ventricular ejection fraction, LVSVI=left ventricular stroke volume index, VMI=ventricular mass 
index, Ea = arterial load and Ees = RV elastance. 
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Table 5 Multivariate analyses showing independent predictors of outcome in the whole 
PAH cohort, all incident patients with PAH and incident patients with IPAH and CTD 
 
 Multivariate 
Hazard ratio 
P value 
Full cohort   
Age >50 2.787 (1.691 to 4.592) <0.0001 
Presence of CTD 1.421 (1.017 to 1.984) 0.039 
Monotherapy vs 
Combination therapy 
1.700 (1.200 to 2.409) 0.003 
SvO2 (scaled) 0.792 (0.672 to 0.934) 0.006 
RV ESV %pred (scaled)  1.217 (1.061 to 1.539) 0.005 
PA RAC (scaled) 0.762 (0.623 to 0.932) 0.008 
Incident cases  
Age >50 2.324 (1.380 to 3.915) 0.002 
Monotherapy vs 
Combination therapy 
1.571 (1.087 to 2.270) 0.016 
SvO2 (scaled) 0.790 (0.661 to 0.944) 0.009 
RV ESV %pred (scaled)  1.186 (1.015 to 1.385) 0.032 
PA RAC (scaled) 0.741 (0.589 to 0.932) 0.010 
Incident IPAH    
Age >50 2.837 (1.200 to 6.708) 0.010 
Female 0.583 (0.360 to 0.945) 0.029 
SvO2 (scaled) 0.652 (0.495 to 0.858) 0.002 
Ees (scaled) 0.781 (0.621 to 0.983) 0.035 
RV ESV %pred (scaled)  1.408 (1.147 to 1.729) 0.001 
Incident CTD   
Monotherapy vs 
Combination therapy 
2.182 (1.282 to 3.714) 0.004 
Ees/Ea (scaled) 0.757 (0.642 to 0.892) 0.001 
PA RAC (scaled) 0.653 (0.496 to 0.859) 0.002 
CTD = connective tissue disease, Svo2= mixed venous oxygen saturations, RVESVI=right ventricular end-
systolic volume index, PA RAC= Pulmonary artery relative area change, Ea = arterial load and Ees = RV 
elastance. 
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Table 6 MRI and demographics model  
 
 Sens Spec PPV NPV LHR p-value 
Full cohort       
  Prognostic model 3 years       
    RV end-systolic volume (%pred) (1.8) 61 63 43 78 1.64 0.0002 
    MRI model (0.13) 71 63 47 83 1.91 <0.0001 
    MRI and demographic model (3.0) 77 73 56 87 2.78 <0.0001 
Sens = sensitivity, Spec= specificity, PPV=positive predictive value, NPV=negative predictive value and 
LHR=likelihood ratio. 
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Online supplement tables 
 
Table a Univariate Cox proportional hazards regression analysis showing prognostic 
significance of demographic, right heart catheterisation (RHC) and MRI data for incident 
treatment naïve patients with PAH 
 
N=398, 189 deaths 
 
Univariate 
Hazard ratio 
 
 
Scaled Univariate 
Hazard ratio 
 
 
P value 
 
Demographics 
   
  Age 
(dichotomised <50 
DQG 
2.852 (1.827 to 4.450)  <0.0001
+ 
  Gender (female %) 0.905 (0.668 to 1.226)  0.519 
  WHO FC     
    I&II vs III&IV 1.708 (0.989 to 2.950)  0.055 
    I-III vs IV    
  IPAH  0.955 (0.717 to 1.274)  0.756 
  CTD 1.271 (0.950 to 1.701)  0.107 
  Congenital 0.595 (0.314 to 1.125)  0.110 
  Other 0.879 (0.541 to 1.430)  0.604 
PAH therapy    
   Monotherapy oral 1.447 (1.074 to 1.949)  0.009 
   Combination oral  0.731 (0.549 to 0.974)  0.033 
   Prostanoid 0.987 (0.677 to 1.438)  0.945 
RHC   
  mPAP (mmHg) 0.997 (0.985 to 1.008) 0.958 (0.825 to 1.112) 0.572 
  mRAP (mmHg) 1.017 (0.991 to 1.044) 1.097 (0.949 to 1.269) 0.209 
  PAWP (mmHg) 0.980 (0.938 to 1.025) 0.935 (0.804 to 1.088) 0.384 
  Svo2 (%) 0.969 (0.954 to 0.984) 0.738 (0.637 to 0.856) <0.0001
+ 
  CI (L.min-1.m-2) 0.797 (0.658 to 0.966) 0.813 (0.682 to 0.969) 0.021 
  PVRI (dyn.s.cm-3) 1.008 (0.991 to 1.027) 1.070 (0.926 to 1.237) 0.358 
Cardiac MR indices    
  RVEDVI %pred 1.005 (1.002 to 1.007) 1.240 (1.085 to 1.416) 0.002 
  RVESVI %pred 1.002 (1.001 to 1.003) 1.326 (1.172 to 1.499) <0.0001
+ 
  RVEF %pred 0.991 (0.985 to 0.998) 0.828 (0.717 to 0.956) 0.010 
  RVSVI %pred 1.000 (0.996 to 1.005) 1.008 (0.869 to 1.169) 0.915 
  LVEDVI %pred 0.994 (0.987 to 1.002) 0.999 (0.997 to 1.000) 0.141 
  LVESVI %pred 1.000 (0.996 to 1.005) 1.000 (0.988 to 1.002) 0.892 
  LVEF %pred 0.994 (0.986 to 1.003) 0.917 (0.801 to 1.049) 0.206 
  LVSVI %pred 0.996 (0.989 to 1.004) 0.897 (0.729 to 1.104) 0.306 
  RV EDM %pred 1.001 (1.000 to 1.002) 1.137 (0.987 to 1.310) 0.076 
  PA forward flow 
index  (l/min/m2) # 
0.942 (0.838 to 1.058) 0.919 (0.780 to 1.083) 0.313 
PA stiffness 
metrics 
   
  PA relative area 
change# 
0.948 (0.926 to 0.972) 0.657 (0.543 to 0.795)  <0.0001
+ 
  PA distensibility* 0.088 (0.022 to 0.360) 0.467 (0.303 to 0.721) 0.001+ 
RV PA coupling 
metrics 
   
  Ea (mmHg/ml/m2)* 1.014 (0.913 to 1.121) 1.017 (0.881 to 1.174) 0.819 
  Ees 
(mmHg/ml/m2)* 
0.892 (0.799 to 0.996) 0.873 (0.766 to 0.995) 0.042 
  Ees /Ea (ratio)* 0.702 (0.566 to 0.872) 0.786 (0.678 to 0.911) 0.001+ 
  MRI Ees /Ea (ratio) 0.592 (0.407 to 0.862) 0.811 (0.698 to 0.943) 0.006 
*N=325 #N=385. +Significant after Bonferonni correction. WHO= world health organisation, IPAH = idiopathic 
pulmonary arterial hypertension, CTD = connective tissue disease,  mRAP=mean right atrial pressure, 
mPAP=mean pulmonary artery pressure, PCWP=pulmonary capillary wedge pressure, PVR=pulmonary vascular 
resistance, CI=cardiac index, Svo2= mixed venous oxygen saturations, RVEDVI=right ventricular end-diastolic 
volume index, RVESVI=right ventricular end-systolic volume index, RVEF=right ventricular ejection fraction, 
LVEDVI=left ventricular end-diastolic volume index, LVESVI=left ventricular end-systolic volume index, 
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LVEF=left ventricular ejection fraction, LVSVI=left ventricular stroke volume index, VMI=ventricular mass 
index, Ea = arterial load and Ees = RV elastance. 
 
 
Table b Univariate Cox proportional hazards regression analysis showing prognostic 
significance of demographic, right heart catheterisation (RHC) and MRI data for incident 
treatment naïve patients with IPAH 
N=179, 84 deaths Univariate 
Hazard ratio 
 
 
Scaled univariate 
Hazard ratio 
(variable/SD) 
 
 
P value 
 
Demographics 
   
    Age (dichotomised 
DQG 
3.881 (1.872 to 8.045)  <0.0001+ 
  Gender (female %) 0.649 (0.422 to 0.997)  0.048 
  WHO FC     
    I&II vs III&IV 2.431 90.978 to 6.043)  0.056 
    I-III vs IV 2.618 (0.650 to 4.155)  <0.0001+ 
PAH therapy    
   Monotherapy oral 1.103 (0.703 to 1.730)  0.670 
   Combination oral  1.106 (0.717 to 1.706)  0.649 
   Prostanoid 0.763 (0.446 to 1.306)  0.325 
RHC   
  mPAP (mmHg) 0.979 (0.959 to 1.000) 0.765 (0.587 to 0.996) 0.046 
  mRAP (mmHg) 1.031 (0.989 to 1.075) 1.186 (0.940 to 1.497) 0.150 
  PAWP (mmHg) 0.982 (0.914 to 1.055) 0.941 (0.738 to 1.199) 0.621 
  Svo2 (%) 0.960 (0.937 to 0.985) 0.680 (0.534 to 0.865) 0.002 
  CI (L.min-1.m-2) 0.781 (0.573 to 1.064) 0.798 (0.602 to 1.058) 0.117 
  PVRI (dyn.s.cm-3) 0.984 (0.950 to 1.019) 0.874 (0.659 to 1.161) 0.354 
Cardiac MR indices    
  RVEDVI %pred 1.007 (1.003 to 1.011) 1.383 (1.133 to 1.688) 0.001+ 
  RVESVI %pred 1.003 (1.001 to 1.004) 1.392 (1.173 to 1.651) <0.0001+ 
  RVEF %pred 0.991 (0.980 to 1.002) 0.828 (0.651 to 1.053) 0.123 
  RVSVI %pred 1.004 (0.997 to 1.011) 1.136 (0.909 to 1.420) 0.261 
  LVEDVI %pred 0.998 (0.986 to 1.010) 1.000 (0.997 to 1.003) 0.779    
  LVESVI %pred 1.308 (0.633 to 2.702) 1.001 (0.988 to 1.004) 0.515 
  LVEF %pred 0.992 (0.979 to 1.004) 0.878 (0.721 to 1.068) 0.193 
  LVSVI %pred 1.002 (0.991 to 1.014) 1.072 (0.778 to 1.477) 0.673 
  RV EDM %pred 1.003 (0.999 to 1.006) 1.203 (0.955 to 1.515) 0.117 
  PA forward flow index  
(l/min/m2) # 
0.863 (0.687 to 1.083) 0.813 (0.591 to 1.119) 0.204 
PA stiffness metrics    
  PA relative area 
change# 
0.951 (0.915 to 0.990) 0.673 (0.492 to 0.921) 0.013 
  PA distensibility* 0.044 (0.004 to 0.438) 0.380 (0.186 to 0.774) 0.008 
RV PA coupling 
metrics 
   
  Ea (mmHg/ml/m2)* 0.823 (0.679 to 0.997) 0.925 (0.743 to 1.150) 0.482 
  Ees (mmHg/ml/m2)* 0.328 (0.157 to 0.684) 0.573 (0.396 to 0.827) 0.003 
  Ees /Ea (ratio)* 0.477 (0.235 to 0.966) 0.603 (0.372 to 0.977) 0.040 
  MRI Ees /Ea (ratio) 0.540 (0.260 to 1.124) 0.749 (0531 to 1.056) 0.100 
*N=149 #N=176. +Significant after Bonferonni correction. WHO= world health organisation, IPAH = idiopathic 
pulmonary arterial hypertension, CTD = connective tissue disease,  mRAP=mean right atrial pressure, 
mPAP=mean pulmonary artery pressure, PCWP=pulmonary capillary wedge pressure, PVR=pulmonary vascular 
resistance, CI=cardiac index, Svo2= mixed venous oxygen saturations, RVEDVI=right ventricular end-diastolic 
volume index, RVESVI=right ventricular end-systolic volume index, RVEF=right ventricular ejection fraction, 
LVEDVI=left ventricular end-diastolic volume index, LVESVI=left ventricular end-systolic volume index, 
LVEF=left ventricular ejection fraction, LVSVI=left ventricular stroke volume index, VMI=ventricular mass 
index, Ea = arterial load and Ees = RV elastance 
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Table c Univariate Cox proportional hazards regression analysis showing prognostic 
significance of demographic, right heart catheterisation (RHC) and MRI data for incident 
treatment naïve patients with PAH-CTD 
 
N=147, 77 deaths Univariate 
Hazard ratio 
 
 
Univariate 
Hazard ratio 
 
 
P value 
 
Demographics 
   
Age (dichotomised <50 
DQG 
1.407 (0.675 to 2.929)  0.362 
  Gender (female %) 0.778 (0.447 to 1.354)  0.374 
  WHO FC     
    I&II vs III&IV 1.416 (0.857 to 2.337)  0.174 
    I-III vs IV 1.167 (0.881 to 3.168)  0.116 
PAH therapy    
   Monotherapy oral 1.568 (0.977 to 2.515)  0.062 
   Combination oral  0.571 (0.364 to 0.896)  0.015 
   Prostanoid 1.440 (0.776 to 2.673)  0.248 
RHC   
  mPAP (mmHg) 1.012 (0.995 to 1.030) 1.171 (0.933 to 1.470) 0.174 
  mRAP (mmHg) 1.000 (0.963 to 1.038) 0.999 (0.809 to 1.234) 0.150 
  PAWP (mmHg) 0.982 (0.922 to 1.047) 0.941 (0.758 to 1.167) 0.578 
  Svo2 (%) 0.964 (0.940 to 0.989) 0.707 (0.556 to 0.889) 0.005 
  CI (L.min-1.m-2) 0.766 (0.576 to 1.019) 0.785 (0.605 to 1.017) 0.067 
  PVRI (dyn.s.cm-3) 0.984 (0.950 to 1.019) 1.073 (0869 to 1.326) 0.354 
Cardiac MR indices    
  RVEDVI %pred 1.004 (0.998 to 1.009) 1.182 (0.897 to 1.558)  0.236 
  RVESVI %pred 1.002 (1.002 to 1.004) 1.258 (1.005 to 1.574) 0.045 
  RVEF %pred 0.990 (0.980 to 1.000) 0.798 (0.642 to 0.990) 0.041 
  RVSVI %pred 0.995 (0.995 to 1.004) 0.844 (0.616 to 1.156) 0.290 
  LVEDVI %pred 0.362 (0.090 to 1.452) 0.997 (0.994 to 1.000)     0.152 
  LVESVI %pred 1.242 (0.582 to 2.648) 1.000 (0.997 to 1.002) 0.575 
  LVEF %pred 0.992 (0.978 to 1.007) 0.886 (0.708 to 1.108) 0.288 
  LVSVI %pred 0.985 (0.972 to 0.997) 0.644 (0.447 to 0.927) 0.018 
  RV EDM %pred 1.001 (0.997 to 1.005) 1.055 (0.804 to 1.383) 0.701 
  PA forward flow index  
(l/min/m2) # 
1.023 (0.804 to 1.300) 1.032 (0.737 to 1.445) 0.855 
PA stiffness metrics    
  PA relative area 
change# 
0.948 (0.914 to 0.982) 0.652 (0.490 to 0.866) 0.003 
  PA distensibility* 0.155 (0.034 to 0.700) 0.560 (0.351 to 0.895)  0.015 
RV PA coupling 
metrics 
   
  Ea (mmHg/ml/m2)* 0.984 (0.984 to 1.360) 1.227 (0.978 to 1.538) 0.077 
  Ees (mmHg/ml/m2)* 0.979 (0.819 to 1.170) 0.975 (0.788 to 1.206) 0.815 
  Ees /Ea (ratio)* 0.607 (0.425 to 0.867) 0.674 (0.508 to 0.894) 0.006 
  MRI Ees /Ea (ratio) 0.521 (0.309 to 0.879) 0.770 (0.625 to 0.950) 0.015 
*N=134 #N=139. WHO= world health organisation, IPAH = idiopathic pulmonary arterial hypertension, CTD = 
connective tissue disease,  mRAP=mean right atrial pressure, mPAP=mean pulmonary artery pressure, 
PCWP=pulmonary capillary wedge pressure, PVR=pulmonary vascular resistance, CI=cardiac index, Svo2= 
mixed venous oxygen saturations, RVEDVI=right ventricular end-diastolic volume index, RVESVI=right 
ventricular end-systolic volume index, RVEF=right ventricular ejection fraction, LVEDVI=left ventricular end-
diastolic volume index, LVESVI=left ventricular end-systolic volume index, LVEF=left ventricular ejection 
fraction, LVSVI=left ventricular stroke volume index, VMI=ventricular mass index, Ea = arterial load and Ees = 
RV elastance. 
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Figure 1  
Images detailing PA size and relative area change analysis (A) maximal PA area and (B) 
minimal PA area and RV volume and mass calculation from end diastolic images (C) and 
end-systolic images (D). 
 
Figure 2  
Study flow diagram 
 
Figure 3 
Kaplan-Meier survival curves showing the outcome of PA relative area change and 
RVESV %pred. Numbers at risk are presented below each plot.  
 
Figure 4  
Receiver operating curves for important predictors of mortality in all patients with PAH 
(a) and incident patients with IPAH (b)  
 
 
 
 
 
